Drugs / DTPa-IPV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00290342 | Jan 2006 → Jan 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01277705 | Jan → Apr 2002 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dTpa-IPV | “A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection.” PMID 15882526 ↗ May 2005 |
| Known as | Boostrix-polio | “received a single decennial booster dose of dTpa-IPV (Boostrix-polio, GlaxoSmithKline Vaccines).” PMID 25882172 ↗ Apr 2015 |
| Modality | Vaccine | “combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus (DTPa-IPV) vaccine” NCT00290342 ↗ |
| Route | Intramuscular | “received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh” NCT00290342 ↗ |